XML 59 R49.htm IDEA: XBRL DOCUMENT
v3.24.3

Significant agreements - Bayer Collaboration Agreement - Accounting Analysis (Details) - Bayer Collaboration Agreement $ in Thousands | May 04, 2023 USD ($) item
--- | ---
Significant agreements. |
Transaction price | $ 47,500
Two combined performance obligations related to the licenses and research and development services associated with radiopharmaceutical compounds directed to the first and second targets |
Significant agreements. |
Combined performance obligations | item | 2
Transaction price | $ 14,976
Material right associated with limited substitution rights for either the first or second target |
Significant agreements. |
Transaction price | $ 1,527
Two material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development |
Significant agreements. |
Number of material rights | item | 2
Transaction price | $ 14,691
Two material rights associated with the option to progress a non-radiopharmaceutical compound directed to the first and second targets |
Significant agreements. |
Number of material rights | item | 2
Transaction price | $ 8,703
Material right for the option to expand the collaboration to include a third target and the underlying additional option rights |
Significant agreements. |
Transaction price | $ 7,603

X
- Definition The number of combined performance obligations. + References No definition available. + Details
Name: | bcyc_NumberOfCombinedPerformanceObligations
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of material rights usually associated with an option. + References No definition available. + Details
Name: | bcyc_NumberOfMaterialRights
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of allocated determined transaction price under revenue recognition arrangement. + References No definition available. + Details
Name: | bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcyc_BayerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |